摘要
目的研究野黄芩素(scutellarein)对高糖诱导的小胶质细胞活化引起的血脑屏障功能障碍的改善。方法将神经小胶质细胞BV-2与小鼠脑血管内皮细胞bEnd.3共培养,建立血脑屏障细胞模型。跨内皮电阻实验和细胞渗漏实验检测内皮细胞屏障的损伤情况;酶联免疫吸附法测定BV2细胞上清中TNF-α的含量;免疫印迹法检测bEnd.3细胞中紧密连接蛋白,包括occludin、claudin1、claudin5和claudin19的表达。结果用高糖诱导活化BV-2细胞或用TNF-α直接刺激bEnd.3细胞都会损伤bEnd.3细胞构成的细胞屏障,野黄芩素可逆转这种损伤。野黄芩素可以减少高糖诱导活化的BV-2细胞中TNF-α的分泌。TNF-α可以降低bEnd.3细胞中紧密连接蛋白claudin1、claudin5和claudin19的表达,野黄芩素能够逆转TNF-α降低的claudin1和claudin19蛋白表达。结论野黄芩素可以阻断高糖诱导的神经小胶质细胞活化,减少炎性因子TNF-α的释放,缓解高糖诱导激活神经小胶质细胞和TNF-α直接刺激脑血管内皮细胞所导致的血脑屏障破损。
Aim To investigate the effect of scutellarein on the blood-brain barrier(BBB)dysfunction mediated by hyperglycemia-stimulated microglia cells.Methods The microglia cells(BV-2)were co-cultured with murine cerebrovascular endothelial cells(bEnd.3)to establish a blood-brain barrier cell model.The damage of endothelial barrier was measured by transendothelial electrical resistance and cell leakage assay.The amount of TNF-α in the supernatant from BV-2 cells was detected by enzyme-linked immunosorbent assay.The effect of scutellarein on the expression of tight junction proteins(including occluding,claudin1,claudin5 and claudin19)was detected by Western blot.Results HG-stimulated BV-2 co-cultured with bEnd.3 or TNF-α directly stimulated bEnd.3 damaged cellular barrier formed by bEnd.3 cells,which could be reversed by scutellarin.Scutellarein decreased the release of pro-inflammatory cytokine TNF-αfrom HG-stimulated microglia cells.TNF-α decreased the expression of tight junction proteins including claudin1,claudin5 and claudin19 in b.End3 cells,but scutellarein reversed such reduction induced by TNF-α.Conclusions Scutellarein decreases the release of pro-inflammatory cytokine TNF-α via abrogating hyperglycemia-stimulated microglia activation,and alleviates BBB dysfunction in brain endothelial cellsb.End3 induced by HG-stimulated microglial cells or TNF-α alone.
作者
王梦娜
梅茜钰
陆宾
徐红
WANG Meng-na;MEI Xi-yu;LU Bin;XU Hong(Institute of Chinese Materia Medica,Shanghai University of Traditional Chinese Medicine,Shanghai Key Lab for Complex Prescription,MOE Key Lab for Standardization of Chinese Medicines,and SATCM Key Lab for New Resources and Quality Evaluation of Chinese Medicines,Shanghai 201203,China)
出处
《中国药理学通报》
CAS
CSCD
北大核心
2020年第11期1542-1547,共6页
Chinese Pharmacological Bulletin
基金
上海市进一步加快中医药事业发展三年行动计划[No ZY(2018-2020)-CCCX-5002]。